

Koichi Amano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4420304/publications.pdf>

Version: 2024-02-01

80
papers

1,659
citations

304743

22
h-index

330143

37
g-index

92
all docs

92
docs citations

92
times ranked

2171
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. <i>Modern Rheumatology</i> , 2023, 33, 64-72.	1.8	2
2	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2022, 32, 59-67.	1.8	6
3	Nation-wide survey of the treatment trend of microscopic polyangiitis and granulomatosis with polyangiitis in Japan using the Japanese Ministry of Health, Labour and Welfare Database. <i>Modern Rheumatology</i> , 2022, 32, 915-922.	1.8	7
4	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2022, 31, 1082-1095.	2.9	1
5	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). <i>Modern Rheumatology</i> , 2022, 32, 263-272.	1.8	10
6	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). <i>Modern Rheumatology</i> , 2022, 32, 273-283.	1.8	3
7	Concurrent Takayasu Arteritis and Vascular Ehlers-Danlos Syndrome: A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 805505.	2.4	1
8	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. <i>Rheumatology</i> , 2022, 61, 4273-4285.	1.9	3
9	Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1452-1463.	0.7	5
10	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 632-640.	0.9	103
11	Vascular endothelial growth factor (VEGF)-A and VEGF-A ₁₆₅ are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 86-94.	1.6	1
12	Kidney GATA3+ regulatory T cells play roles in the convalescence stage after antibody-mediated renal injury. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1249-1261.	10.5	31
13	Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies. <i>Modern Rheumatology</i> , 2021, 31, 205-213.	1.8	3
14	Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2021, 23, 91.	3.5	5
15	Exploratory classification of clinical phenotypes in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis using cluster analysis. <i>Scientific Reports</i> , 2021, 11, 5223.	3.3	5
16	Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2178.	7.4	103
17	Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 228.	3.5	9
18	Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech. <i>Frontiers in Medicine</i> , 2021, 8, 751598.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Safety and tolerability of sifalimumab, an anti-interferon- γ monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. <i>Modern Rheumatology</i> , 2020, 30, 93-100.	1.8	23
20	Predictive value of serum amyloid A levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. <i>Modern Rheumatology</i> , 2020, 30, 442-449.	1.8	2
21	Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. <i>Rheumatology</i> , 2020, 59, 1617-1621.	1.9	25
22	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 94-102.	0.9	13
23	Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. <i>Arthritis Research and Therapy</i> , 2020, 22, 236.	3.5	14
24	A case of polyangiitis overlap syndrome of giant cell arteritis and granulomatosis with polyangiitis successfully treated with rituximab. <i>Modern Rheumatology Case Reports</i> , 2020, 5, 1-5.	0.7	3
25	Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 46.	3.5	19
26	JCS 2017 Guideline on Management of Vasculitis Syndrome – Digest Version. <i>Circulation Journal</i> , 2020, 84, 299-359.	1.6	59
27	The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate-associated lymphoproliferative disorders. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 41-50.	0.8	9
28	2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. <i>Modern Rheumatology</i> , 2019, 29, 20-30.	1.8	47
29	Tocilizumab monotherapy for polymyalgia rheumatica: A prospective, single-center, open-label study. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 2151-2157.	1.9	21
30	Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2019, 60, 2508-2515.	1.3	8
31	FRI0099...PREDICTIVE FACTORS FOR REMISSION ACHIEVEMENT BY TOCILIZUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER INADEQUATE RESPONSE TO METHOTREXATE: A POST HOC ANALYSIS OF THE SURPRISE STUDY. , 2019, , .		0
32	Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 387-394.	1.6	9
33	Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018, 28, 444-451.	1.8	6
34	Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. <i>Leukemia and Lymphoma</i> , 2018, 59, 1143-1152.	1.3	49
35	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. <i>Modern Rheumatology</i> , 2018, 28, 583-591.	1.8	36
36	Association Between Reappearance of Myeloperoxidase Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1626-1633.	5.6	34

#	ARTICLE	IF	CITATIONS
37	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1268-1275.	0.9	43
38	Successful treatment with tocilizumab monotherapy for Takayasu arteritis developing during infliximab therapy in a patient with ulcerative colitis. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 174-176.	0.7	4
39	Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 621.	4.8	21
40	Era of steroid sparing in the management of immune-mediated inflammatory diseases. <i>Immunological Medicine</i> , 2018, 41, 6-11.	2.6	13
41	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. <i>Rheumatology</i> , 2017, 56, 1293-1301.	1.9	19
42	Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. <i>Arthritis Research and Therapy</i> , 2017, 19, 117.	3.5	10
43	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. <i>Modern Rheumatology</i> , 2017, 27, 811-819.	1.8	10
44	Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. <i>Clinical Rheumatology</i> , 2017, 36, 2383-2392.	2.2	36
45	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. <i>Scientific Reports</i> , 2017, 7, 15035.	3.3	23
46	Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study. <i>Modern Rheumatology</i> , 2017, 27, 646-651.	1.8	25
47	Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. <i>Modern Rheumatology</i> , 2017, 27, 787-794.	1.8	5
48	Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e018748.	1.9	16
49	Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2017, 19, 218.	3.5	40
50	Discussion on Management of Rheumatic Diseases for Elderly Patients. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 2170-2181.	0.0	0
51	Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 159.	3.5	38
52	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1917-1923.	0.9	81
53	Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. <i>Modern Rheumatology</i> , 2016, 26, 730-737.	1.8	39
54	Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. <i>Modern Rheumatology</i> , 2016, 26, 900-907.	1.8	18

#	ARTICLE	IF	CITATIONS
55	V. Giant Cell Arteritis. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2015, 104, 2139-2142.	0.0	1
56	Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 305.	3.5	41
57	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. <i>Arthritis Research and Therapy</i> , 2015, 17, 74.	3.5	53
58	Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. <i>Modern Rheumatology</i> , 2015, 25, 665-671.	1.8	11
59	Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis. <i>Cytokine</i> , 2015, 75, 222-227.	3.2	16
60	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. <i>Journal of Rheumatology</i> , 2015, 42, 799-809.	2.0	39
61	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. <i>Rheumatology</i> , 2015, 54, 683-691.	1.9	39
62	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2014, 24, 17-25.	1.8	105
63	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	1
64	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. <i>Modern Rheumatology</i> , 2013, , 1.	1.8	5
65	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. <i>Modern Rheumatology</i> , 2013, 23, 945-952.	1.8	20
66	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). <i>Modern Rheumatology</i> , 2012, 22, 327-338.	1.8	38
67	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. <i>Modern Rheumatology</i> , 2012, 22, 186-194.	1.8	6
68	Differences between the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified HAQ (mHAQ) score before and after infliximab treatment in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2010, 20, 337-342.	1.8	9
69	Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2009, 19, 351-357.	1.8	75
70	Molecular effects to human regulatory T cells by treatment with T cell activation inhibitor and TNF blockade. <i>FASEB Journal</i> , 2008, 22, 1073.10.	0.5	0
71	Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. <i>Modern Rheumatology</i> , 2007, 17, 92-97.	1.8	26
72	Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis. <i>APLAR Journal of Rheumatology</i> , 2007, 10, 295-299.	0.2	3

#	ARTICLE	IF	CITATIONS
73	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006, 16, 381-388.	1.8	16
74	Impact of TNF inhibitors on rheumatoid arthritis. <i>Inflammation and Regeneration</i> , 2006, 26, 148-159.	3.7	3
75	Amebiasis in Acquired Immunodeficiency Syndrome. <i>Internal Medicine</i> , 2001, 40, 563-564.	0.7	8
76	Candida pneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999, 9, 397-402.	0.0	0
77	Candidapneumonia in a case of polymyositis complicated with interstitial pneumonitis. <i>Japanese Journal of Rheumatology</i> , 1999, 9, 397-402.	0.0	0
78	Nosocomial Pneumonia Likely Caused by <i>Stenotrophomonas Maltophilia</i> in Two Patients with Polymyositis.. <i>Internal Medicine</i> , 1999, 38, 910-916.	0.7	4
79	Integrin VLA-5 Negative Primary Plasma Cell Leukemia.. <i>Internal Medicine</i> , 1993, 32, 565-568.	0.7	5
80	Clinical studies of renal disorders in patients with rheumatoid arthritis.. <i>Japanese Journal of Clinical Immunology</i> , 1992, 15, 135-141.	0.0	0